Learning objectives: To understand the range of epigenetic modifiers mutated in kidney cancer.

To describe the consequences of SETD2 loss or haploinsufficiency in mitosis.

Session date: 
03/01/2022 - 12:00pm to 1:00pm CST
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
W. Kimryn Rathmell, MD, PhD